Merck, Daiichi Sankyo withdraw US application for lung cancer drug

1

Sept 25 (Reuters) – Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday. (

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)